Literature DB >> 16426000

Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population.

Emaeil Porsa1, Lee Cheng, Michael M Seale, George L Delclos, Xin Ma, Robert Reich, James M Musser, Edward A Graviss.   

Abstract

Screening for latent tuberculosis infection (LTBI) with Mantoux tuberculin skin test (TST) has many limitations, including false-positive results due to exposure to Mycobacterium other than tuberculosis (TB) and BCG vaccination. A total of 474 adult inmates in a county jail were screened for LTBI using TST and a new ESAT-6/CFP-10 peptide-based whole-blood gamma interferon (IFN-gamma) assay. LTBI prevalence was 9.0 and 5.4% as determined by TST and IFN-gamma assay, respectively. Overall, agreement between test results was 90% (kappa = 0.25). Positive TST results were significantly associated with increased age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.01 to 1.08), African-American ethnicity (OR, 4.97; 95% CI, 1.58 to 15.68), foreign birth (OR, 20.20; 95% CI, 4.21 to 97.02) and prior incarceration (OR, 6.19; 95% CI, 1.48 to 25.95). Positive IFN-gamma assay results were significantly associated with African-American ethnicity (OR, 5.58; 95% CI, 1.16 to 26.74). Factors associated with statistically significant discordance between TST and IFN-gamma assay results were African-American ethnicity (OR, 0.29; 95% CI, 0.11 to 0.77), foreign birth (OR, 0.23; 95% CI, 0.07-0.80), and prior incarceration (OR, 0.06; 95% CI, 0.01-0.50). Among subjects born in the United States, African-American ethnicity was the only variable significantly associated with positive test results for both TST (OR, 4.26; 95% CI, 1.38 to 13.16) and IFN-gamma assay (OR, 5.74; 95% CI, 1.19 to 27.75) and remained associated with statistically significant discordance between TST and IFN-gamma assay results. The reactivity of the new IFN-gamma assay is unaffected by prior BCG vaccination or serial TSTs but may be diminished in African-Americans. Future longitudinal studies are needed to assess the sensitivity and specificity of this new assay in detecting LTBI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426000      PMCID: PMC1356632          DOI: 10.1128/CVI.13.1.53-58.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  27 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

Review 2.  Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

Review 3.  Jails, prisons, and the health of urban populations: a review of the impact of the correctional system on community health.

Authors:  N Freudenberg
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

4.  Kappa statistics in the assessment of observer variation: the significance of multiple observers classifying ankle fractures.

Authors:  Niels O B Thomsen; Lars H Olsen; Steen T Nielsen
Journal:  J Orthop Sci       Date:  2002       Impact factor: 1.601

5.  Evaluation of an extensive tuberculosis contact investigation in an urban community and jail.

Authors:  S Bur; J E Golub; J A Armstrong; K Myers; B H Johnson; D Mazo; J F Fielder; H Rutz; G Maltas; R McClain; W A Cronin; N G Baruch; L F Barker; W Benjamin; T R Sterling
Journal:  Int J Tuberc Lung Dis       Date:  2003-12       Impact factor: 2.373

6.  Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection.

Authors:  Giovanni Ferrara; Monica Losi; Marisa Meacci; Barbara Meccugni; Roberto Piro; Pietro Roversi; Barbara Maria Bergamini; Roberto D'Amico; Patrizia Marchegiano; Fabio Rumpianesi; Leonardo M Fabbri; Luca Richeldi
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

7.  Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact.

Authors:  S M Arend; A C Engelhard; G Groot; K de Boer; P Andersen; T H Ottenhoff; J T van Dissel
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

8.  Unrecognised transmission of tuberculosis in prisons.

Authors:  C R MacIntyre; N Kendig; L Kummer; S Birago; N M Graham; A J Plant
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

9.  Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment.

Authors:  A A Pathan; K A Wilkinson; P Klenerman; H McShane; R N Davidson; G Pasvol; A V Hill; A Lalvani
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

10.  Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10.

Authors:  I Brock; M E Munk; A Kok-Jensen; P Andersen
Journal:  Int J Tuberc Lung Dis       Date:  2001-05       Impact factor: 2.373

View more
  13 in total

1.  Reproducibility of QuantiFERON-TB gold in-tube assay.

Authors:  Sharon Perry; Luz Sanchez; Shufang Yang; Zubin Agarwal; Philip Hurst; Julie Parsonnet
Journal:  Clin Vaccine Immunol       Date:  2008-01-16

2.  Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.

Authors:  Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2007-01-11       Impact factor: 21.405

3.  Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections.

Authors:  Raffaella Palazzo; Fabiana Spensieri; Marco Massari; Giorgio Fedele; Loredana Frasca; Stefania Carrara; Delia Goletti; Clara M Ausiello
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

4.  Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice.

Authors:  John Z Metcalfe; Adithya Cattamanchi; Charles E McCulloch; Justin D Lew; Ngan P Ha; Edward A Graviss
Journal:  Am J Respir Crit Care Med       Date:  2012-10-26       Impact factor: 21.405

5.  Comparison of an ESAT-6/CFP-10 peptide-based enzyme-linked immunospot assay to a tuberculin skin test for screening of a population at moderate risk of contracting tuberculosis.

Authors:  Esmaeil Porsa; Lee Cheng; Edward A Graviss
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

6.  Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation.

Authors:  Eliane M S Leyten; Sandra M Arend; Corine Prins; Frank G J Cobelens; Tom H M Ottenhoff; Jaap T van Dissel
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

7.  Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA.

Authors:  Ank E Nijhawan; Princess A Iroh; Larry S Brown; Daniel Winetsky; Esmaeil Porsa
Journal:  BMC Infect Dis       Date:  2016-10-12       Impact factor: 3.090

Review 8.  Current issues on molecular and immunological diagnosis of tuberculosis.

Authors:  Sang-Nae Cho
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

9.  Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis.

Authors:  Jean-Michel Hougardy; Kinda Schepers; Sammy Place; Annie Drowart; Véronique Lechevin; Virginie Verscheure; Anne-Sophie Debrie; T Mark Doherty; Jean-Paul Van Vooren; Camille Locht; Françoise Mascart
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

10.  Tuberculin Skin Test among 1,424 Healthy Employees in Chaharmahal Province, Iran.

Authors:  Mehdi Besharat; Farhad Abbasi
Journal:  Tanaffos       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.